Age
Item
age ≥ 18
boolean
C0001779 (UMLS CUI [1])
Breast Carcinoma
Item
histological proven cancer of the breast.
boolean
C0678222 (UMLS CUI [1])
Progressive Disease | Neoplasm Metastasis
Item
progressive and/or metastatic disease.
boolean
C1335499 (UMLS CUI [1])
C0027627 (UMLS CUI [2])
Standard therapy Unavailable | Standard therapy Patient Unwilling
Item
no further standard treatment for the patient available or the patient does not wish to receive the offered standard treatment.
boolean
C2936643 (UMLS CUI [1,1])
C0686905 (UMLS CUI [1,2])
C2936643 (UMLS CUI [2,1])
C0030705 (UMLS CUI [2,2])
C0558080 (UMLS CUI [2,3])
Hormone Therapy | Skin lesion Progression
Item
if endocrine therapy: progression in cutaneous lesions.
boolean
C0279025 (UMLS CUI [1])
C0037284 (UMLS CUI [2,1])
C0242656 (UMLS CUI [2,2])
trastuzumab | Herceptin | Skin lesion Regression Absent
Item
if treatment with trastuzumab (herceptin)can continue this treatment if there is no regression in cutaneous lesions.
boolean
C0728747 (UMLS CUI [1])
C0338204 (UMLS CUI [2])
C0037284 (UMLS CUI [3,1])
C0684320 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
Chemotherapy | Navelbine | vinorelbine | capecitabine | Xeloda | Paclitaxel | Taxol | Secondary malignant neoplasm of skin Regression Absent
Item
at least 2 weeks since last chemotherapy, patients treated with navelbine (vinorelbine), capecitabin (xeloda) or weekly paclitaxel (taxol)can continue this treatment if there is no regression in cutaneous metastases.
boolean
C0392920 (UMLS CUI [1])
C0131965 (UMLS CUI [2])
C0078257 (UMLS CUI [3])
C0671970 (UMLS CUI [4])
C0724419 (UMLS CUI [5])
C0144576 (UMLS CUI [6])
C0678133 (UMLS CUI [7])
C0153687 (UMLS CUI [8,1])
C0684320 (UMLS CUI [8,2])
C0332197 (UMLS CUI [8,3])
Skin lesion Malignant Size | Lesion subcutaneous Malignant Size
Item
malignant cutaneous or subcutaneous lesion to be treated ≥ 3 cm.
boolean
C0037284 (UMLS CUI [1,1])
C0205282 (UMLS CUI [1,2])
C0456389 (UMLS CUI [1,3])
C0221198 (UMLS CUI [2,1])
C0443315 (UMLS CUI [2,2])
C0205282 (UMLS CUI [2,3])
C0456389 (UMLS CUI [2,4])
WHO performance status scale
Item
who performance ≤ 2.
boolean
C1298650 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 3 months.
boolean
C0023671 (UMLS CUI [1])
Platelet Count measurement | APTT measurement
Item
platelets ≥ 50 mia/l, pp ≥ 40, aptt in normal area. medical correction is allowed.
boolean
C0032181 (UMLS CUI [1])
C0030605 (UMLS CUI [2])
Study Subject Sexually active Contraceptive methods
Item
sexual active men and women must use safe anticonceptive during and up to 6 month after last treatment.
boolean
C0681850 (UMLS CUI [1,1])
C0241028 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,3])
Informed Consent
Item
written informed consent must be obtained according to the local ethics committee requirements.
boolean
C0021430 (UMLS CUI [1])
Infectious disease of lung
Item
acute lung infection
boolean
C0876973 (UMLS CUI [1])
Bleomycin Dosage
Item
previous bleomycin treatment exceeding 200.000 units/m2.
boolean
C0005740 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
Hypersensitivity Component Therapeutic procedure
Item
known hypersensitivity to any of the components of the treatment.
boolean
C0020517 (UMLS CUI [1,1])
C1705248 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
Hypersensitivity Component Anesthesia Planned
Item
known hypersensitivity to any of the components used in the planned anesthesia.
boolean
C0020517 (UMLS CUI [1,1])
C1705248 (UMLS CUI [1,2])
C0002903 (UMLS CUI [1,3])
C1301732 (UMLS CUI [1,4])
Pregnancy | Breast Feeding | Childbearing Potential Blood human chorionic gonadotropin
Item
pregnant or lactating women. in fertile women this is ensured by measuring hcg in blood.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0853985 (UMLS CUI [3,2])
Granulocyte Colony-Stimulating Factor | cytokine
Item
treatment with granulocyte colony stimulating factor (g-csf) or other cytokines.
boolean
C0079459 (UMLS CUI [1])
C0079189 (UMLS CUI [2])